ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathy.

Quan Dong Nguyen Justis P EhlersDavid S BoyerXidong JinAndrea GianiMichael S Ehrlichnull null

Published in: Eye (London, England) (2024)

BI 1467335 was well tolerated by patients with NPDR. There was a high variability in DRSS levels for individual patients over time, with no clear efficacy signal.

Keyphrases

diabetic retinopathy
placebo controlled
end stage renal disease
double blind
newly diagnosed
clinical trial
ejection fraction
chronic kidney disease
study protocol
optical coherence tomography
prognostic factors
peritoneal dialysis
open label
randomized controlled trial
phase iii